secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001104659-25-091066
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune completes Type A FDA meeting for RP1 BLA in melanoma; path forward uncertain
--------------------------------------------------------------------------------

- Completed Type A FDA meeting on Sept 16, 2025 regarding CRL for RP1+nivolumab BLA in advanced melanoma.
- Evaluating FDA feedback; accelerated approval path not yet determined.
- CEO cites unmet need and compelling IGNYTE trial risk-benefit; committed to working with FDA.
- No timeline or resolution provided; stock may remain volatile pending updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925091066/0001104659-25-091066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925091066/tm2526397d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-091066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer